Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, has warned that profits and sales could fall by as much as 13% this year, marking its first potential decline in years. The Danish pharmaceutical giant cited heavy U.S. price pressure, intensifying competition in the obesity drug market, and expiring patents on semaglutide as key challenges weighing on its outlook.
The warning brings an end to a long streak of double-digit growth that began after the launch of Wegovy in June 2021, which helped fuel soaring demand for obesity treatments and turned Novo Nordisk into Europe’s most valuable listed company in 2024, with a market capitalization of around $600 billion. Since peaking in mid-2024, however, the company’s valuation has fallen sharply, with shares losing roughly two-thirds of their value.
Novo Nordisk now expects both adjusted operating profit and adjusted sales, measured at constant exchange rates, to decline between 5% and 13% this year. This compares with a 10% rise in sales last year and analysts’ prior expectations of only a modest decline. The company pointed to lower realized prices, especially in the U.S. market, as well as growing competition from rival drugs and copycat versions.
CEO Mike Doustdar acknowledged pricing headwinds in an increasingly competitive market but expressed confidence in long-term volume growth, highlighting early demand for the newly launched Wegovy pill in the United States. Novo is also reshaping its leadership team, with new executives stepping in to lead U.S. operations and product strategy.
Investor concerns intensified after Novo’s U.S.-listed shares fell 12% following the announcement. Analysts noted that pricing concessions linked to U.S. drug policy under President Donald Trump could further pressure revenues in 2026. The broader obesity drug sector also felt the impact, with shares of competitors such as Eli Lilly and smaller biotech firms sliding amid fears of tougher competition.
Despite near-term challenges, Novo Nordisk is betting on innovation, marketing, and new formulations to defend its position in the fast-evolving weight-loss drug market.
